Any current/future new fundraising through debt or equity?

No major fresh capex or significant investments are planned at the Morbi facility currently; ongoing improvements are expected instead (Page 11). The company has completed major capex related to rail assets; presently, they are seeking a few more rakes on long-term lease but no immediate asset purchases planned (Page 7). No specific mention of new fundraising through debt or equity in the current call transcript. The company has been focusing on becoming debt-free and optimizing costs (Page 8). Existing investments and capex are being concluded mostly in FY24, with no fresh major investments i

Any current/future capex/capital investment/strategic investment?

Major capex at Morbi is almost concluded, with the project moving into operational stage. No significant fresh capex is planned at Morbi currently, only ongoing improvement and maintenance activities. Maintenance capex is estimated at INR 10-15 crores annually. Total investment at Morbi including CWIP stands around INR 450 crores. Capex on rail assets mostly done, with current fleet comprising seven rakes and one more arriving soon. Future additional rakes will likely be taken on long-term lease; no immediate fresh asset purchases planned. Overall, the company anticipates capex realization/pay

Future growth expectations in sales/revenue/volumes?

Domestic movement is expected to increase by 10% to 15% post monsoon in FY '24 and FY '25. CFS business will continue steadily; if export quota opens fully (especially for sugar), export numbers could jump by 25% to 30%. Rice export quota opening may add another 5% growth. ICD-Morbi import and export volumes are projected to grow around 15% to 20%. Overall revenue and profitability are expected to improve over the next couple of quarters. Significant medium-term revenue and profit improvement anticipated as Morbi operations mature. Export markets (especially agro-commodities) likely to remain

Future growth expectations in earnings/operating earnings/profits/EPS?

Domestic rail movement expected to grow by 10-15% post-monsoon in FY24 and FY25. Export growth tied to government quotas: sugar export quota opening could increase export volumes by 25-30%; rice export opening could add another 5%. Morbi ICD business projected to grow strongly with import/export volumes expected to increase 15-20%. Overall revenue and profitability expected to improve in the coming quarters as Morbi operations mature. Short-term outlook cautious due to subdued EXIM trade and agro-commodity export restrictions linked to elections and government policies. Medium-term outlook pos

Navkar Corporat.Q2 FY24

Navkar Corporat. Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹85.1P/E: 33.2Market Cap: ₹1.3K Cr

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

N/A

Capex

0 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Domestic movement is expected to increase by 10% to 15% post monsoon in FY '24 and FY '25.
CFS business will continue steadily; if export quota opens fully (especially for sugar), export numbers could jump by 25% to 30%.
Rice export quota opening may add another 5% growth.
ICD-Morbi import and export volumes are projected to grow around 15% to 20%.
Overall revenue and profitability are expected to improve over the next couple of quarters.
Significant medium-term revenue and profit improvement anticipated as Morbi operations mature.
Export markets (especially agro-commodities) likely to remain subdued till after the elections but expected to recover thereafter.
No major price hikes expected in rail business in the short term; focus is on volume growth and operational efficiencies.

Margin guidance

Category 3

Domestic rail movement expected to grow by 10-15% post-monsoon in FY24 and FY25.
Export growth tied to government quotas: sugar export quota opening could increase export volumes by 25-30%; rice export opening could add another 5%.
Morbi ICD business projected to grow strongly with import/export volumes expected to increase 15-20%.
Overall revenue and profitability expected to improve in the coming quarters as Morbi operations mature.
Short-term outlook cautious due to subdued EXIM trade and agro-commodity export restrictions linked to elections and government policies.
Medium-term outlook positive with business diversification into rail and domestic segments improving operational efficiencies.
Earnings impact currently limited by increased depreciation and interest due to recent capex but expected to normalize over 7-8 years payback period.
No immediate price hikes or dividends are anticipated; wealth creation expected via volume and operational gains over time.

See what Navkar Corporat. management said on margin guidance — free account, 30 seconds.

Fundraise plans

No major fresh capex or significant investments are planned at the Morbi facility currently; ongoing improvements are expected instead (Page 11).
The company has completed major capex related to rail assets; presently, they are seeking a few more rakes on long-term lease but no immediate asset purchases planned (Page 7).
No specific mention of new fundraising through debt or equity in the current call transcript.
The company has been focusing on becoming debt-free and optimizing costs (Page 8).
Existing investments and capex are being concluded mostly in FY24, with no fresh major investments indicated (Page 11).
No explicit guidance or announcements related to raising funds via debt or equity were provided during the Q&A or management remarks (entire transcript).

Order book

The transcript provided does not explicitly mention the current or expected order book or pending orders for Navkar Corporation Limited. However, key points related to business outlook and growth prospects include: - Morbi ICD operations are growing robustly with new customer acquisitions and expanding commodity coverage. - Domestic rail transportation is expected to improve post-monsoon, with an anticipated volume increase of 10% to 15% domestically. - If export quotas open (e.g., for sugar), export volumes could jump by 25% to 30%; rice export opening may add another 5%. - Morbi import and export volumes are estimated to grow 15% to 20%. - No specific figures on order book or pending orders were disclosed in the transcript. In summary, while a robust growth outlook is indicated, no concrete data on order book or pending orders is provided.

See what Navkar Corporat. management said on order book — free account, 30 seconds.

Capex plans

Major capex at Morbi is almost concluded, with the project moving into operational stage.
No significant fresh capex is planned at Morbi currently, only ongoing improvement and maintenance activities.
Maintenance capex is estimated at INR 10-15 crores annually.
Total investment at Morbi including CWIP stands around INR 450 crores.
Capex on rail assets mostly done, with current fleet comprising seven rakes and one more arriving soon.
Future additional rakes will likely be taken on long-term lease; no immediate fresh asset purchases planned.
Overall, the company anticipates capex realization/payback in 7-8 years due to nature of business.
No concrete plans for new business expansions or additional facilities at this moment, but open to opportunities if they arise.

Track Navkar Corporat. — get its next earnings analysis in your feed

How does Navkar Corporat. rank vs peers in ?

Pro feature

ThisNavkar Corporat.

Rev 3Mar 3

See where Navkar Corporat. sits in See which companies these are, and every other name in the sector.Open rankings

What Navkar Corporat.'s management said in earlier quarters

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Navkar Corporat. Q2 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

Continue your research

What Navkar Corporat.'s management said in earlier quarters